



July 9, 2012

Peregrine to Report Fourth Quarter and Fiscal Year 2012 Financial Results After Market Close on July 16, 2012

TUSTIN, CA -- (Marketwire) -- 07/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it will report financial results for the fourth quarter and fiscal year 2012 on July 16, 2012 after market close and will host a conference call and webcast at 4:30 p.m. EDT (1:30 p.m. PDT). Peregrine's senior management will discuss financial results for the fourth quarter and fiscal year ended April 30, 2012 and will review its clinical development programs.

To listen to the live webcast or access the archived webcast available for 30 days, please visit:
<http://ir.peregrineinc.com/events.cfm>.

To listen to the conference call, please call (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through July 30, 2012 by calling (855) 859-2056 or (404) 537-3406 and using passcode 97304760.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact:

Christopher Keenan or Jay Carlson

Peregrine Pharmaceuticals

(800) 987-8256

info@peregrineinc.com

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media